Advertisement
UK markets closed
  • NIKKEI 225

    37,961.80
    -509.40 (-1.32%)
     
  • HANG SENG

    16,251.84
    +2.87 (+0.02%)
     
  • CRUDE OIL

    82.65
    -2.71 (-3.17%)
     
  • GOLD FUTURES

    2,378.70
    -29.10 (-1.21%)
     
  • DOW

    37,666.54
    -132.43 (-0.35%)
     
  • Bitcoin GBP

    48,531.96
    -1,706.98 (-3.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    15,684.28
    -180.97 (-1.14%)
     
  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     

Medigene AG to present at upcoming investor conferences

Medigene AG
Medigene AG

Planegg/Martinsried, May 8, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the following upcoming investor conferences:


Bio€quity Europe 2023

https://conferences.biocentury.com/bioequity-europe

Date: May 14-16, 2023, Dublin, Ireland
Presentation: Monday, May 15, 2:33 – 2:45 pm (local time)
Presenter: Dr. Selwyn Ho, CEO


German Spring Conference 2023

https://equityforum.de/en/events/fr-hjahrskonferenz-2023

Date: May 15-17, 2023, Frankfurt, Germany
Presentation: Wednesday, May 17, 9:15 - 9:55 am (local time)
Presenter: Dr. Selwyn Ho, CEO

ADVERTISEMENT

Medigene’s management team will be available for one-on-one meetings at the events. Please contact Julia von Hummel of MC Services at  julia.vonhummel@mc-services.eu to schedule a meeting.

---  end of press release  ---

About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com

Pamela Keck
Phone: +49 89 2000 3333 01
Email: investor@medigene.com

MC Services

Julia von Hummel
Phone: +49 89 210 228 34
Email: Julia.vonHummel@mc-services.eu

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.